TECX Tectonic Therapeutic, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1681087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-72.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.5%
ROA-33.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio19.71x
Interest coverage-3,216.43x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $63.49M | $41.36M |
| SG&A expense | $20.55M | $16.65M |
| Operating income | -$84.04M | -$58.02M |
| Interest expense | $63,000 | $107,000 |
| Pretax income | -$72.92M | -$57.98M |
| Income tax | $1.23M | $0 |
| Net income | -$74.15M | -$57.98M |
| EBITDA | -$82.66M | -$56.37M |
| EPS (basic) | -4.05 | -6.83 |
| EPS (diluted) | -4.05 | -6.83 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 18.32M | 8.49M |
| Balance sheet | ||
| Cash & equivalents | $253.80M | $141.83M |
| Current assets | $257.36M | $146.86M |
| PP&E, net | $1.19M | $2.15M |
| Total assets | $261.04M | $152.91M |
| Current liabilities | $9.67M | $11.61M |
| Total liabilities | $9.71M | $12.13M |
| Shareholders' equity | $251.33M | $140.78M |
| Shares outstanding | 18.74M | 14.86M |
| Cash flow statement | ||
| Operating cash flow | -$60.08M | -$59.08M |
| Capital expenditure | $208,000 | $156,000 |
| Free cash flow | -$60.29M | -$59.24M |
| Investing cash flow | -$138,000 | -$156,000 |
| Financing cash flow | $173.35M | $171.71M |
| Depreciation & amortization | $1.38M | $1.65M |
| Stock-based compensation | $10.50M | $3.49M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.